What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

This research aimed to evaluate the safety and efficacy of combining bevacizumab and temsirolimus in patients with advanced malignancies.

December 11, 2025The OncologistOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase I trial finds safety of bevacizumab and temsirolimus in advanced malignancies, suggesting modest activity in ovarian cancer.

This research aimed to evaluate the safety and efficacy of combining bevacizumab and temsirolimus in patients with advanced malignancies.
Phase I study design
48 heavily pretreated patients with advanced solid tumors
Combination therapy biweekly bevacizumab plus weekly temsirolimus
Exploratory analyses included tumor genomic profiling and DCE-MRI
93.8% experienced treatment-related adverse events
Maximum tolerated dose established at bevacizumab 10 mg/kg and temsirolimus 20 mg
Overall objective response rate was 7.3%
In the ovarian cohort, objective response rate was 16.7%
26.8% clinical benefit rate observed with stable disease ≥6 months

Piha‐Paul et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark